logo
Plus   Neg
Share
Email

PDL BioPharma Decides To Pursue Monetization Of Its Assets - Quick Facts

PDL BioPharma, Inc. (PDLI) has decided to pursue a formal process to unlock value by monetizing the company's assets and returning net proceeds to shareholders. The decision followed the the strategic review process that it initiated in September.

PDL will explore a variety of potential transactions, including a sale of the company, divestiture of its assets or businesses, a spin-off transaction, a merger or a combination. The company has decided to halt the execution of its growth strategy, and cease additional strategic investments.

Also, PDL's Board has authorized the repurchase of issued and outstanding shares of the company's common stock and convertible notes up to an aggregate value of $200 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
RELATED NEWS
Follow RTT